The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Bosentan Improves Exercise Capacity in Adolescents and Adults After Fontan Operation: The TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) Study
Open accessAbstract
Background—: The Fontan procedure has improved survival in children with functionally univentricular hearts. With time, however, complications such as reduced exercise capacity are seen more frequently. Exercise intolerance is multifactorial, but pulmonary vascular resistance probably plays a crucial role. Elevated pulmonary vascular resistance has been associated with raised levels of endothelin-1, which are common both before and after Fontan operations. Treatment with endothelin-1 receptor antagonists could theoretically improve cardiopulmonary hemodynamics and exercise capacity. The aim of this study was therefore to examine the efficacy and safety of bosentan in Fontan patients. Methods and Results—: Seventy-five adolescents and adults were randomized 1:1 to 14 weeks of treatment with bosentan or placebo. Cardiopulmonary exercise test, functional class, blood samples, and quality-of-life questionnaires were evaluated at baseline and at the end of treatment. Sixty-nine patients (92%) completed the study. Peak oxygen consumption increased 2.0 mL·kg −1 ·min −1 (from 28.7 to 30.7 mL·kg −1 ·min −1 ) in the bosentan group compared with 0.6 mL·kg −1 ·min −1 (from 28.4 to 29.0 mL·kg −1 ·min −1 ) in the placebo group ( P =0.02). Cardiopulmonary exercise test time increased by 0.48 minute (from 6.79 to 7.27 minutes) versus 0.08 minute (from 6.94 to 7.02 minutes; P =0.04). Nine bosentan-treated patients improved 1 functional class, whereas none improved in the placebo group ( P =0.0085). Side effects were mild and occurred equally in both groups. No serious adverse effects were seen, and no patients had liver enzyme levels above the 3-fold upper limit. Conclusions—: Bosentan improves exercise capacity, exercise time, and functional class in Fontan patients without serious adverse events or hepatotoxicity. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01292551.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diller, G.-P., Dimopoulos, K., Okonko, D., Li, W., Babu-Narayan, S. V., Broberg, C. S., Johansson, B., Bouzas, B., Mullen, M. J., Poole-Wilson, P. A., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.529800 · Cited by 878
Cited by
2020 ESC Guidelines for the management of adult congenital heart disease
Baumgartner, H., De Backer, J., Babu-Narayan, S. V., Budts, W., Chessa, M., Diller, G.-P., lung, B., Kluin, J., Lang, I. M., Meijboom, F., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa554 · Cited by 2,311
Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000603 · Cited by 1,602
2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease
Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1029 · Cited by 1,080
Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., Crumb, S. R., Dearani, J. A., Fuller, S., Gurvitz, M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000602 · Cited by 533
Metadata
- Authors
- Hebert, A., Mikkelsen, U. R., Thilen, U., Idorn, L., Jensen, A. S., Nagy, E., Hanseus, K., Sørensen, K. E., & Søndergaard, L.
- Venue
- Circulation
- Published
- 2014-12-02
- Volume
- 130
- Issue
- 23
- Pages
- 2021-2030
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1996680410
- Cited by
- 216
- References
- 1
- FWCI
- 13.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bosentan Improves Exercise Capacity in Adolescents and Adults After Fontan Operation: The TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) Study. https://app.cochat.ai/papers/10.1161/circulationaha.113.008441
- The paper
- Hebert, A., Mikkelsen, U. R., Thilen, U., Idorn, L., Jensen, A. S., Nagy, E., Hanseus, K., Sørensen, K. E., & Søndergaard, L. (2014). Bosentan Improves Exercise Capacity in Adolescents and Adults After Fontan Operation: The TEMPO (Treatment With Endothelin Receptor Antagonist in Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen Consumption) Study. Circulation. https://doi.org/10.1161/circulationaha.113.008441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.